{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:17:58Z","timestamp":1783948678832,"version":"3.55.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T00:00:00Z","timestamp":1372723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1038\/nrgastro.2013.106","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T10:27:31Z","timestamp":1372760851000},"page":"596-606","source":"Crossref","is-referenced-by-count":119,"title":["Drug\u2013drug interactions during antiviral therapy for chronic hepatitis C"],"prefix":"10.1038","volume":"10","author":[{"given":"Jennifer J.","family":"Kiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James R.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T.","family":"Everson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,2]]},"reference":[{"key":"BFnrgastro2013106_CR1","unstructured":"WHO. Hepatitis C Fact Sheet. WHO [online] , (2013)."},{"key":"BFnrgastro2013106_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1042\/CS20080631","volume":"117","author":"H Tang","year":"2012","unstructured":"Tang, H. & Grise, H. Cellular and molecular biology of HCV infection and hepatitis. Clin. Sci. (Lond.) 117, 49\u201365 (2012).","journal-title":"Clin. Sci. (Lond.)"},{"key":"BFnrgastro2013106_CR3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.7326\/0003-4819-125-8-199610150-00002","volume":"125","author":"NN Zein","year":"1996","unstructured":"Zein, N. N. et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann. Intern. Med. 125, 634\u2013639 (1996).","journal-title":"Ann. Intern. Med."},{"key":"BFnrgastro2013106_CR4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon, B. R. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207\u20131217 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2013106_CR5","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405\u20132416 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2013106_CR6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1195\u20131206 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2013106_CR7","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417\u20132428 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 2","key":"BFnrgastro2013106_CR8","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S0168-8278(12)60025-7","volume":"56","author":"JP Bronowicki","year":"2012","unstructured":"Bronowicki, J. P. et al. Sustained virologic response (SVR) in prior peginterferon\/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) + PR: the PROVIDE study interim results [abstract 11]. J. Hepatol. 56 (Suppl. 2) S6 (2012).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2013106_CR9","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","volume":"365","author":"KE Sherman","year":"2011","unstructured":"Sherman, K. E. et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365, 1014\u20131024 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2013106_CR10","doi-asserted-by":"crossref","unstructured":"Merck. Victrelis \u00a9 (boceprevir) prescribing information. Merck [online] , (2013).","DOI":"10.22233\/20412495.0413.6"},{"key":"BFnrgastro2013106_CR11","unstructured":"Vertex. Incivek\u2122 (telaprevir) prescribing information. Vertex [online] , (2013)."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR12","first-page":"1429A","volume":"54","author":"MW Fried","year":"2011","unstructured":"Fried, M. W. et al. TMC435 in combination with peginterferon and ribavirin in treatment naive hcv genotype 1 patients: final analysis of the pillar phase IIb study [abstract LB-5]. Hepatology 54 (Suppl. 1), 1429A (2011).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR13","first-page":"474A","volume":"54","author":"C Hezode","year":"2011","unstructured":"Hezode, C. et al. BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results [abstract 227]. Hepatology 54 (Suppl. 1), 474A (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR14","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/hep.26276","volume":"57","author":"MS Sulkowski","year":"2013","unstructured":"Sulkowski, M. S. et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatology 57, 2143\u20132154 (2013).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR15","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","volume":"381","author":"KV Kowdley","year":"2013","unstructured":"Kowdley, K. V. et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 381, 2100\u20132107 (2013).","journal-title":"Lancet."},{"key":"BFnrgastro2013106_CR16","unstructured":"Sulkowski, M. S. et al. All-ORAL Combination of DCV + SOF \u00b1 RBV in treatment-na\u00efve patients with HCV GT 1, 2 or 3 [abstract LB2]. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (2012)."},{"key":"BFnrgastro2013106_CR17","doi-asserted-by":"crossref","unstructured":"Everson, G. T. et al. An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment-na\u00efve patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection [abstract LB3]. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (2012).","DOI":"10.1016\/S0168-8278(13)61422-1"},{"key":"BFnrgastro2013106_CR18","unstructured":"Kowdley, K. V. et al. A 12-week interferon-free treatment regimen with ABT-450\/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (OBSERVED Data) of 99% in treatment-na\u00efve patients and 93% in prior null responders with HCV genotype 1 infection [abstract LB1]. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (2012)."},{"issue":"Suppl. 6","key":"BFnrgastro2013106_CR19","first-page":"230A","volume":"56","author":"AS Lok","year":"2012","unstructured":"Lok, A. S. et al. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A Inhibitor) and asunaprevir (ASV; NS3 Inhibitor) with or without peginterferon alfa-2a\/ribavirin (PEG\/RBV) [abstract 79]. Hepatology 56 (Suppl. 6), 230A (2012).","journal-title":"Hepatology"},{"issue":"Suppl. 6","key":"BFnrgastro2013106_CR20","first-page":"231A","volume":"56","author":"JJ Feld","year":"2012","unstructured":"Feld, J. J. et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB), and ribavirin (R) \u00b1 peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study [abstract 81]. Hepatology 56 (Suppl. 6), 231A (2012).","journal-title":"Hepatology"},{"issue":"Suppl. 6","key":"BFnrgastro2013106_CR21","first-page":"556A","volume":"56","author":"AJ Thompson","year":"2012","unstructured":"Thompson, A. J. et al. Six weeks of a NS5A Inhibitor (GS-5885), protease inhibitor (GS-9451) plus peginterferon\/ribavirin (PR) achieves high SVR4 rates in genotype 1 IL28B CC treatment naive HCV patients: interim results of a prospective, randomized trial [abstract 759]. Hepatology 56 (Suppl. 6), 556A (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/archinte.162.4.405","volume":"162","author":"DA Flockhart","year":"2002","unstructured":"Flockhart, D. A., Tanus-Santos, J. E. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch. Intern. Med. 162, 405\u2013412 (2002).","journal-title":"Arch. Intern. Med."},{"key":"BFnrgastro2013106_CR23","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","volume":"58","author":"D Burger","year":"2013","unstructured":"Burger, D. et al. Clinical management of drug\u2013drug interactions in HCV therapy: challenges and solutions. J. Hepatol. 58, 792\u2013800 (2013).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2013106_CR24","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1034\/j.1600-0676.2001.021004260.x","volume":"21","author":"C Herold","year":"2001","unstructured":"Herold, C. et al. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 21, 260\u2013265 (2001).","journal-title":"Liver"},{"key":"BFnrgastro2013106_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","volume":"80","author":"RF Frye","year":"2006","unstructured":"Frye, R. F. et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin. Pharmacol. Ther. 80, 235\u2013245 (2006).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR26","first-page":"678A","volume":"56","author":"SM Helmke","year":"2012","unstructured":"Helmke, S. M., DeSanto, J., Herman, A., Lauriski, S. & Everson, G. T. Alteration of the portal circulation across the entire spectrum of fibrosis in patients with chronic Hepatitis C as measured by dual cholate clearances [abstract 1005]. Hepatology 56 (Suppl. 1), 678A (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cld.2011.05.014","volume":"15","author":"S Ciesek","year":"2011","unstructured":"Ciesek, S., von Hahn, T. & Manns, M. P. Second-wave protease inhibitors: choosing an heir. Clin. Liver Dis. 15, 597\u2013609 (2011).","journal-title":"Clin. Liver Dis."},{"key":"BFnrgastro2013106_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/07853890.2011.572905","volume":"43","author":"MW Hull","year":"2011","unstructured":"Hull, M. W. & Montaner, J. S. Ritonavir-boosted protease inhibitors in HIV therapy. Ann. Med. 43, 375\u2013388 (2011).","journal-title":"Ann. Med."},{"key":"BFnrgastro2013106_CR29","first-page":"951","volume":"11","author":"M Deutsch","year":"2010","unstructured":"Deutsch, M. & Papatheodoridis, G. V. Danoprevir, a small-molecule NS3\/4A protease inhibitor for the potential oral treatment of HCV infection. Curr. Opin. Investig. Drugs 11, 951\u2013963 (2010).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnrgastro2013106_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jhep.2013.02.009","volume":"59","author":"E Lawitz","year":"2013","unstructured":"Lawitz, E. et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450\/r, ABT-072) and ribavirin in IL28B C\/C patients with chronic hepatitis C genotype 1. J. Hepatol. 59, 18\u201323 (2013).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2013106_CR31","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/jac\/dkt032","volume":"68","author":"CT de Kanter","year":"2013","unstructured":"de Kanter, C. T. et al. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole. J. Antimicrob. Chemother. 68, 1415\u20131422 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrgastro2013106_CR32","unstructured":"Merck. Boceprevir Clinical Pharmacology and Biopharmaceutics Review. FDA [online] , (2013)."},{"key":"BFnrgastro2013106_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/BF03261935","volume":"51","author":"M Treitel","year":"2012","unstructured":"Treitel, M. et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin. Pharmacokinet. 51, 619\u2013628 (2012).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrgastro2013106_CR34","unstructured":"Buti, M. et al. OPTIMIZE Trial: Noninferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naive, genotype 1 HCV-infected patients [abstract LB-8]. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (2012)."},{"key":"BFnrgastro2013106_CR35","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.bcp.2012.07.032","volume":"84","author":"A Kunze","year":"2012","unstructured":"Kunze, A., Huwyler, J., Camenisch, G. & Gutmann, H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem. Pharmacol. 84, 1096\u20131102 (2012).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrgastro2013106_CR36","first-page":"3","volume":"6","author":"B Adiwijaya","year":"2011","unstructured":"Adiwijaya, B. et al. Effect of mild and moderate hepatic impairment on telaprevir pharmacokinetics [abstract PK1]. Reviews in Antiviral Therapy & Infectious Diseases 6, 3 (2011).","journal-title":"Reviews in Antiviral Therapy & Infectious Diseases"},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR37","first-page":"S416","volume":"52","author":"V Sekar","year":"2010","unstructured":"Sekar, V. et al. TMC435 and Drug Interactions: Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers [abstract 1076]. J. Hepatol. 52 (Suppl. 1), S416 (2010).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR38","first-page":"461A","volume":"52","author":"MT Huisman","year":"2010","unstructured":"Huisman, M. T. et al. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters [abstract 278]. Hepatology 52 (Suppl. 1), 461A (2010).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR39","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1016\/S0168-8278(11)60474-1","volume":"54","author":"V Sekar","year":"2011","unstructured":"Sekar, V. et al. Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment [abstract 472]. J. Hepatol. 54 (Suppl. 1), S193 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2013106_CR40","unstructured":"Sabo, J. P. et al. Cytochrome P450 (CYP) interactions with the HCV protease inhibitor faldaprevir (BI 201335) in healthy volunteers [abstract A-1248]. Presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (2012)."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR41","doi-asserted-by":"publisher","first-page":"S488","DOI":"10.1016\/S0168-8278(11)61238-5","volume":"54","author":"R Sane","year":"2011","unstructured":"Sane, R. et al. Mechanism of isolated unconjugated hyperbilirubinemia induced by the HCV NS3\/4A protease inhibitor BI 201335 [abstract 1236]. J. Hepatol. 54 (Suppl. 1), S488 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2013106_CR42","unstructured":"Kort, J. Clinical pharmacology update on the direct acting antivirals faldaprevir and BI 207127. Presented at the 14th International Workshop on Clinical Pharmacology of HIV Therapy (2013)."},{"key":"BFnrgastro2013106_CR43","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.cld.2011.05.010","volume":"15","author":"RG Gish","year":"2011","unstructured":"Gish, R. G. & Meanwell, N. A. The NS5A replication complex inhibitors: difference makers? Clin. Liver Dis. 15, 627\u2013639 (2011).","journal-title":"Clin. Liver Dis."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR44","first-page":"991A","volume":"54","author":"M Bifano","year":"2011","unstructured":"Bifano, M. et al. BMS-790052 has no clinically significant effect on the pharmacokinetics ofa combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects [abstract 1340]. Hepatology 54 (Suppl. 1), 991A\u2013992A (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR45","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1002\/hep.24609","volume":"54","author":"RE Nettles","year":"2011","unstructured":"Nettles, R. E. et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54, 1956\u20131965 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR46","unstructured":"Bertz, R. Bristol Myers Squibb HCV full development portfolio overview. Presented at the 14th International Workshop on Clinical Pharmacology of HIV Therapy (2013)."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR47","first-page":"1004A","volume":"54","author":"M Bifano","year":"2011","unstructured":"Bifano, M. et al. Single-dose pharmacokinetics of daclatasvir in subjects with hepatic impairment compared with healthy subjects [abstract 1362]. Hepatology 54 (Suppl. 1), 1004A (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR48","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.3390\/v2102169","volume":"2","author":"MH Powdrill","year":"2010","unstructured":"Powdrill, M. H., Bernatchez, J. A. & Gotte, M. Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B. Viruses 2, 2169\u20132195 (2010).","journal-title":"Viruses"},{"key":"BFnrgastro2013106_CR49","unstructured":"Mathias, A. Clinical Pharmacology of DAAs for HCV: what's new and what's in the pipeline. Presented at the 14th International Workshop on Clinical Pharmacology of HIV Therapy (2013)."},{"issue":"Suppl. 2","key":"BFnrgastro2013106_CR50","doi-asserted-by":"publisher","first-page":"S433","DOI":"10.1016\/S0168-8278(12)61113-1","volume":"56","author":"M Cornpropst","year":"2012","unstructured":"Cornpropst, M. et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977 [abstract 1101]. J. Hepatol. 56 (Suppl. 2), S433 (2012).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR51","doi-asserted-by":"publisher","first-page":"S445","DOI":"10.1016\/S0168-8278(12)61142-8","volume":"56","author":"E Lawitz","year":"2012","unstructured":"Lawitz, E. et al. The effect of hepatic impairment on the safety, pharmacokinetics, and antiviral activity of GS-7977 in hepatitis C infected subjects treated for seven days [abstract 1130]. J. Hepatol. 56 (Suppl. 1) S445\u2013S446 (2012).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR52","first-page":"1000A","volume":"54","author":"M Beumont-Mauviel","year":"2011","unstructured":"Beumont-Mauviel, M. et al. The pharmacokinetic interaction between the investigational HCV NS3\/4A protease inhibitor TMC435 and escitalopram [abstract 1353]. Hepatology 54 (Suppl. 1), 1000A (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR53","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/hep.25653","volume":"55","author":"JJ Kiser","year":"2012","unstructured":"Kiser, J. J., Burton, J. R., Anderson, P. L. & Everson, G. T. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 55, 1620\u20131628 (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR54","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/hep.25831","volume":"56","author":"E Hulskotte","year":"2012","unstructured":"Hulskotte, E. et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 56, 1622\u20131630 (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/hep.24443","volume":"54","author":"V Garg","year":"2011","unstructured":"Garg, V. et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54, 20\u201327 (2011).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR56","first-page":"213A","volume":"56","author":"S Ouwerkerk-Mahadevan","year":"2012","unstructured":"Ouwerkerk-Mahadevan, S., Simion, A., Mortier, S., Peeters, M. & Beumont-Mauviel, M. No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus [abstract 80]. Hepatology 56 (Suppl. 1), 213A (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR57","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1053\/jlts.2003.50233","volume":"9","author":"M Kugelmas","year":"2003","unstructured":"Kugelmas, M. et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 9, 1159\u20131165 (2003).","journal-title":"Liver Transpl."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR58","first-page":"1063A","volume":"56","author":"A Mathias","year":"2012","unstructured":"Mathias, A., Cornpropst, M., Clemons, D., Denning, J. & Symonds, W. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine a or tacrolimus in healthy volunteers [abstract 1869]. Hepatology 56 (Suppl. 1) 1063A\u20131064A (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR59","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/lt.23623","volume":"19","author":"JG O'Leary","year":"2013","unstructured":"O'Leary, J. G., McKenna, G. J., Klintmalm, G. B. & Davis, G. L. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl. 19, 463\u2013465 (2013).","journal-title":"Liver Transpl."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR60","first-page":"297A","volume":"56","author":"JR Burton","year":"2012","unstructured":"Burton, J. R. et al. A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: report from the CRUSH-C Group [abstract 211]. Hepatology 56 (Suppl. 1), 297A (2012).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR61","first-page":"194A","volume":"56","author":"A Coilly","year":"2012","unstructured":"Coilly, A. et al. Efficacy and safety of protease inhibitors for hepatitis C recurrence after liver transplantation: a first multicentric experience [abstract 9]. Hepatology 56 (Suppl. 1), 194A\u2013195A (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR62","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/lt.23542","volume":"18","author":"CR Werner","year":"2012","unstructured":"Werner, C. R. et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl. 18, 1464\u20131470 (2012).","journal-title":"Liver Transpl."},{"key":"BFnrgastro2013106_CR63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cld.2012.09.013","volume":"17","author":"JR Burton Jr","year":"2013","unstructured":"Burton, J. R. Jr & Everson, G. T. Management of the transplant recipient with chronic hepatitis C. Clin. Liver Dis. 17, 73\u201391 (2013).","journal-title":"Clin. Liver Dis."},{"key":"BFnrgastro2013106_CR64","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1097\/00007890-199812270-00009","volume":"66","author":"M Cantarovich","year":"1998","unstructured":"Cantarovich, M. et al. Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 66, 1621\u20131627 (1998).","journal-title":"Transplantation"},{"key":"BFnrgastro2013106_CR65","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2007.11.009","volume":"48","author":"MS Sulkowski","year":"2008","unstructured":"Sulkowski, M. S. Viral hepatitis and HIV coinfection. J. Hepatol. 48, 353\u2013367 (2008).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2013106_CR66","unstructured":"Kasserra, C., Hughes, E., Treitel, M., Gupta, S. & O'Mara, E. Clinical pharmacology of boceprevir: metabolism, excretion, and drug\u2013drug interactions [abstract 118]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections (2011)."},{"key":"BFnrgastro2013106_CR67","doi-asserted-by":"publisher","unstructured":"van Heeswijk, R. P., Beumont, M., Kauffman, R. S. & Garg, V. Review of drug interactions with telaprevir and antiretrovirals. Antivir. Ther. http:\/\/dx.doi.org\/10.3851\/IMP2527 .","DOI":"10.3851\/IMP2527"},{"key":"BFnrgastro2013106_CR68","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/cid\/cis824","volume":"56","author":"CT de Kanter","year":"2013","unstructured":"de Kanter, C. T., Blonk, M. I., Colbers, A. P., Schouwenberg, B. J. & Burger, D. M. Lack of a clinically significant drug\u2013drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin. Infect. Dis. 56, 300\u2013306 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrgastro2013106_CR69","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/cid\/cis968","volume":"56","author":"EG Hulskotte","year":"2012","unstructured":"Hulskotte, E. G. et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin. Infect. Dis. 56, 718\u2013726 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrgastro2013106_CR70","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/cid\/cir882","volume":"54","author":"DL Thomas","year":"2012","unstructured":"Thomas, D. L. et al. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin. Infect. Dis. 54, 979\u2013983 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrgastro2013106_CR71","unstructured":"Kakuda, T. N. et al. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, two-way crossover trial [abstract O-18]. Presented at the 13th International Workshop on Clinical Pharmacology of HIV Therapy (2012)."},{"key":"BFnrgastro2013106_CR72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/QAI.0b013e318275da93","volume":"62","author":"KP Hammond","year":"2013","unstructured":"Hammond, K. P. et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV\/HCV seronegative volunteers. J. Acquir. Immune Defic. Syndr. 62, 67\u201373 (2013).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"BFnrgastro2013106_CR73","unstructured":"Rhee, E. G. et al. Absence of a significant pharmacokinetic interaction between the HCV protease inhibitor boceprevir and HIV-1 NNRTI rilpivirine [abstract 537]. Presented at the 20th Conference on Retroviruses and Opportunistic Infections (2013)."},{"key":"BFnrgastro2013106_CR74","doi-asserted-by":"crossref","unstructured":"Vourvahis, M., Plotka, A., Kantaridis, C., Fang, A. & Heera, J. The effect of boceprevir or telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed sequence study in healthy volunteers [abstract O-17]. Presented at the 14th International Workshop on Clinical Pharmacology of HIV Therapy (2013).","DOI":"10.1097\/QAI.0000000000000090"},{"key":"BFnrgastro2013106_CR75","unstructured":"Sabo, J. P. et al. Pharmacokinetic interactions of darunavir\/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers [abstract 35]. Presented at the 20th Conference on Retroviruses and Opportunistic Infections (2013)."},{"key":"BFnrgastro2013106_CR76","unstructured":"Bifano, M. et al. Assessment of HIV antiretroviral drug interactions with the HCV NS5A replication complex inhibitor daclatasvir demonstrates a PK profile which supports coadministration with tenofovir, efavirez, and atazanavir\/r [abstract 61B]. Presented at the 19th Conference on Retroviruses and Opportunistic Infections (2012)."},{"key":"BFnrgastro2013106_CR77","unstructured":"Ouwerkerk-Mahadevan, S., Sekar, V., Simion, A., Peeters, M. & Beumont-Mauviel, M. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers [abstract 36620]. Presented at Infectious Diseases Week (2012)."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR78","first-page":"1067A","volume":"56","author":"B Kirby","year":"2012","unstructured":"Kirby, B. et al. No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretroviral atripla, rilpivirine, darunavir\/ritonavir, or raltegravir in healthy volunteers [abstract 1877]. Hepatology 56 (Suppl. 1), 1067A (2012.","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR79","first-page":"1078A","volume":"56","author":"WH Lin","year":"2012","unstructured":"Lin, W. H. et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ethinyl estradiol\/norethindrone [abstract 1901]. Hepatology 56 (Suppl. 1), 1078A\u20131079A (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR80","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/0091270011419855","volume":"52","author":"V Garg","year":"2012","unstructured":"Garg, V. et al. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J. Clin. Pharmacol. 52, 1574\u20131583 (2012).","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR81","first-page":"565A","volume":"56","author":"S Ouwerkerk-Mahadevan","year":"2012","unstructured":"Ouwerkerk-Mahadevan, S., Simion, A., Spittaels, K., Peeters, M. & Beumont-Mauviel, M. No pharmacokinetic interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and an oral contraceptive containing ethinylestradiol and norethindrone [abstract 773]. Hepatology 56 (Suppl. 1), 565A\u2013566A (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR82","unstructured":"Pfizer. Viagra\u00ae (sildenafil citrate) prescribing information. Pfizer [online] , (2013)."},{"key":"BFnrgastro2013106_CR83","unstructured":"GlaxosSmithKline. Levitra (vardenafil hydrochloride) prescribing information. GlaxoSmithKline [online] , (2013)."},{"key":"BFnrgastro2013106_CR84","unstructured":"Lilly. Cialis (tadalafil) prescribing information. Lilly [online] , (2013)."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR85","first-page":"1076A","volume":"56","author":"P Jumes","year":"2012","unstructured":"Jumes, P. et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and prednisone in healthy volunteers [abstract 1896]. Hepatology 56 (Suppl. 1), 1076A (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR86","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1345\/aph.1P731","volume":"45","author":"JK Frankel","year":"2011","unstructured":"Frankel, J. K. & Packer, C. D. Cushing's syndrome due to antiretroviral-budesonide interaction. Ann. Pharmacother. 45, 823\u2013824 (2011).","journal-title":"Ann. Pharmacother."},{"key":"BFnrgastro2013106_CR87","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11908-011-0229-1","volume":"14","author":"A Tseng","year":"2012","unstructured":"Tseng, A. & Foisy, M. Important drug\u2013drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs. Curr. Infect. Dis. Rep. 14, 67\u201382 (2012).","journal-title":"Curr. Infect. Dis. Rep."},{"key":"BFnrgastro2013106_CR88","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","volume":"84","author":"HS Smith","year":"2009","unstructured":"Smith, H. S. Opioid metabolism. Mayo Clin. Proc. 84, 613\u2013624 (2009).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrgastro2013106_CR89","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/chir.10303","volume":"16","author":"JG Gerber","year":"2004","unstructured":"Gerber, J. G., Rhodes, R. J. & Gal, J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16, 36\u201344 (2004).","journal-title":"Chirality"},{"key":"BFnrgastro2013106_CR90","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0090-9556(25)07765-7","volume":"12","author":"EJ Cone","year":"1884","unstructured":"Cone, E. J., Gorodetzky, C. W., Yousefnejad, D., Buchwald, W. F. & Johnson, R. E. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 12, 577\u2013581 (1884).","journal-title":"Drug Metab. Dispos."},{"key":"BFnrgastro2013106_CR91","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1128\/AAC.02262-12","volume":"57","author":"R van Heeswijk","year":"2013","unstructured":"van Heeswijk, R. et al. Pharmacokinetic interaction between telaprevir and methadone. Antimicrob. Agents Chemother. 57, 2304\u20132309 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrgastro2013106_CR92","unstructured":"Luo, X., Trevejo, J., Van Heeswijk, R. & Garg V. No significant effect of the HCV protease inhibitor telaprevir on the pharmacokinetics and pharmacodynamics of buprenorphine in HCV-negative volunteers [abstract 132]. Presented at HepDART Koloa, Hawaii (2011)."},{"key":"BFnrgastro2013106_CR93","unstructured":"Hulskotte, E. G. J. et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy [abstract 771LB]. Presented at the 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy (2012)."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR94","first-page":"1000A","volume":"54","author":"M Beumont-Mauviel","year":"2011","unstructured":"Beumont-Mauviel, M., De Smedt, G., Peeters, M., Akuma, S. H. & Sekar, V. The pharmacokinetic interaction between the investigational NS3\u20134A HCV protease inhibitor TMC435 and methadone [abstract 1353]. Hepatology 54 (Suppl. 1), 1000A (2011).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR95","first-page":"544A","volume":"54","author":"J Denning","year":"2011","unstructured":"Denning, J. et al. Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone pharmacokinetics and pharmacodynamics [abstract 372]. Hepatology 54 (Suppl. 1) 544A (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR96","doi-asserted-by":"publisher","first-page":"f1","DOI":"10.1136\/bmj.f1","volume":"346","author":"M Pirmohamed","year":"2013","unstructured":"Pirmohamed, M. Drug\u2013grapefruit juice interactions: two mechanisms are clear but individual responses vary. BMJ 346, f1 (2013).","journal-title":"BMJ"},{"key":"BFnrgastro2013106_CR97","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hep.22044","volume":"47","author":"LB Seeff","year":"2008","unstructured":"Seeff, L. B. et al. Herbal product use by persons enrolled in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) Trial. Hepatology 47, 605\u2013612 (2008).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR98","first-page":"1003A","volume":"56","author":"G Kipp","year":"2012","unstructured":"Kipp, G., Mohammed, R., Lin, A. & Johnson, H. Evaluation of pharmacist identified and mitigated drug\u2013drug interactions in hepatitis C virus infected patients starting telaprevir or boceprevir [abstract 1741]. Hepatology 56 (Suppl. 1), 1003A (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR99","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/03602530600754065","volume":"38","author":"CJ van den Bout-van den Beukel","year":"2006","unstructured":"van den Bout-van den Beukel, C. J., Koopmans, P. P., van der Ven, A. J., De Smet, P. A. & Burger, D. M. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab. Rev. 38, 477\u2013514 (2006).","journal-title":"Drug Metab. Rev."},{"key":"BFnrgastro2013106_CR100","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1592\/phco.30.8.797","volume":"30","author":"SR Penzak","year":"2010","unstructured":"Penzak, S. R. et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir\u2013ritonavir exposure in healthy subjects. Pharmacotherapy 30, 797\u2013805 (2010).","journal-title":"Pharmacotherapy"},{"key":"BFnrgastro2013106_CR101","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1128\/AAC.01082-10","volume":"55","author":"J Molto","year":"2011","unstructured":"Molto, J. et al. Herb\u2013drug interaction between Echinacea purpurea and darunavir\u2013ritonavir in HIV-infected patients. Antimicrob. Agents Chemother. 55, 326\u2013330 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrgastro2013106_CR102","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1592\/phco.22.8.551.33205","volume":"22","author":"SC Piscitelli","year":"2002","unstructured":"Piscitelli, S. C. et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 22, 551\u2013556 (2002).","journal-title":"Pharmacotherapy"},{"key":"BFnrgastro2013106_CR103","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1128\/AAC.00025-12","volume":"56","author":"J Molto","year":"2012","unstructured":"Molto, J. et al. Effect of milk thistle on the pharmacokinetics of darunavir\u2013ritonavir in HIV-infected patients. Antimicrob. Agents Chemother. 56, 2837\u20132841 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrgastro2013106_CR104","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1086\/324351","volume":"34","author":"SC Piscitelli","year":"2002","unstructured":"Piscitelli, S. C., Burstein, A. H., Welden, N., Gallicano, K. D. & Falloon, J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis. 34, 234\u2013238 (2002).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrgastro2013106_CR105","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/0091270011407194","volume":"52","author":"CY Malati","year":"2012","unstructured":"Malati, C. Y. et al. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J. Clin. Pharmacol. 52, 932\u2013939 (2012).","journal-title":"J. Clin. Pharmacol."},{"key":"BFnrgastro2013106_CR106","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1185\/030079908X260871","volume":"24","author":"SM Robertson","year":"2008","unstructured":"Robertson, S. M. Effect of ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr. Med. Res. Opin. 24, 591\u2013599 (2008).","journal-title":"Curr. Med. Res. Opin."},{"key":"BFnrgastro2013106_CR107","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1046\/j.1365-2125.2002.01683.x","volume":"54","author":"L Henderson","year":"2002","unstructured":"Henderson, L., Yue, Q. Y., Bergquist, C., Gerden, B. & Arlett, P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br. J. Clin. Pharmacol. 54, 349\u2013356 (2002).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrgastro2013106_CR108","unstructured":"Bernstein, B. et al. Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers [abstract 58]. Presented at HepDART Kohala Coast, Hawaii (2009)."},{"key":"BFnrgastro2013106_CR109","unstructured":"Menon, R. et al. Pharmacokinetics, safety and tolerability following multiple dosing of polymerase inhibitor, ABT-333 and protease inhibitor, ABT-450 with ritonavir [abstract O-13]. Presented at the 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy (2012)."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR110","first-page":"548A","volume":"54","author":"T Eley","year":"2011","unstructured":"Eley, T. et al. Evaluation of drug interaction potential of the HCV protease inhibitor asunaprevir (ASV; BMS-650032) at 200 mg twice daily (BID) in metabolic cocktail and p-glycoprotein (P-gp) probe studies in health volunteers [abstract 381]. Hepatology 54 (Suppl. 1), 548A (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR111","unstructured":"Eley, T. et al. In vivo and in vitro assessment of asunaprevir (ASV; BMS-650032) as an inhibitor and substrate of organic anion transport polypeptide (OATP) transporters in healthy volunteers [abstract O-04]. Presented at the 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy (2012)."},{"key":"BFnrgastro2013106_CR112","unstructured":"Jumes, P. et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and digoxin in healthy adult volunteers [abstract O-05]. Presented at the 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy (2012)."},{"key":"BFnrgastro2013106_CR113","unstructured":"Marcos, P. N. et al. Danoprevir"},{"key":"BFnrgastro2013106_CR114","doi-asserted-by":"publisher","first-page":"S475","DOI":"10.1016\/S0168-8278(11)61206-3","volume":"54","author":"E Dumas","year":"2011","unstructured":"Dumas, E. et al. Pharmacokinetics, safety and tolerability of the HCV NS5A inhibitor ABT-267 following single and multiple doses in healthy adult volunteers [abstract 1204]. J. Hepatol. 54, S475 (2011).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR115","first-page":"537A","volume":"54","author":"S Moreira","year":"2011","unstructured":"Moreira, S. et al. The effect of mild to moderate renal impairment on the pharmacokinetics (PK) of the hepatitis C virus (HCV) polymerase inhibitor mericitabine (MCB, RG7128) [abstract 358]. Hepatology 54 (Suppl. 1), 537A\u2013538A (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2013106_CR116","doi-asserted-by":"publisher","first-page":"29812","DOI":"10.1074\/jbc.M705274200","volume":"282","author":"H Ma","year":"2007","unstructured":"Ma, H. et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species. J. Biol. Chem. 282, 29812\u201329820 (2007).","journal-title":"J. Biol. Chem."},{"issue":"Suppl. 1","key":"BFnrgastro2013106_CR117","first-page":"S346","volume":"50","author":"C Maring","year":"2009","unstructured":"Maring, C. et al. Preclinical potency, pharmacokinetic and ADME characterization of ABT-333, a novel non-nucleoside HCV polymerase inhibitor [abstract 953]. J. Hepatol. 50 (Suppl. 1), S346\u2013S347 (2009).","journal-title":"J. Hepatol."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2013.106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2013.106","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2013.106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T12:47:48Z","timestamp":1746017268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2013.106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,2]]},"references-count":117,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["BFnrgastro2013106"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2013.106","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,2]]}}}